First-Line Treatment of Claudin 18.2-Positive Metastatic Pancreatic Cancer with Zolbetuximab, Gemcitabine, and Nab-Paclitaxel
Dr. Wungki Park presents an intriguing study of zolbetuximab in this MEDtalk. This innovative monoclonal antibody, which is the first of its kind, targets CLDN 18.2 and induces ADCC/CDC in patients with metastatic pancreatic cancer.
